MétaCan
Menu
← Back to cohort

Abstract B19: Induction of apoptosis and antitumor activity of the AKT inhibitor AZD5363 is enhanced by combination with hormonal therapies in preclinical models of prostate cancer

2012· article· en· W2080126527 on OpenAlexaff
Claire Crafter, Barry R. Davies, Christian Thomas, François Lamoureux, Hannah E. Greenwood, Juan Manuel García‐Martínez, Lorraine Mooney, Sabina Cosulich, Martin Gleave, Amina Zoubeidi

Bibliographic record

VenueCancer Research · 2012
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsAstraZeneca (Canada)University of British Columbia
Fundersnot available
KeywordsLNCaPPTENProstate cancerCancer researchProtein kinase BBicalutamideGrowth inhibitionAndrogen receptorIn vivoEnzalutamideMedicineCancerCell growthPI3K/AKT/mTOR pathwayApoptosisInternal medicineBiologyBiochemistry

Abstract

fetched live from OpenAlex

Abstract Activation of AKT by mechanisms including loss of the tumor suppressors PTEN and INPP4B is very common in prostate cancer, and has been correlated with poor prognosis and progression to androgen independent disease. Recently, a reciprocal feedback mechanism has been shown to occur between the androgen and AKT signalling axes in prostate cancer models. AZD5363 monotherapy induced apoptosis and inhibited growth of PTEN null, AR+ prostate cancer cell lines including LNCaP, C4-2 and a flutamide resistant variant of PC346C (GI50 10 – 100 nM), and showed moderate anti-proliferative activity in AR amplified, PTEN wild type VCaP cells (GI50 ∼ 1 μM). The PTEN wild type, AR negative DU-145, BPH1 and RWPE1 cell lines were relatively resistant. Monotherapy AZD5363 also caused dosedependent growth inhibition of the PTEN null, AR+ HID28 prostate cancer explant model in vivo. Treatment with AZD5363 increased expression of a panel of androgen regulated genes in LNCaP cells, whereas the same panel of genes was down-regulated when AZD5363 was combined with the novel anti-androgen MDV-3100. Combination of AZD5363 with MDV-3100 resulted in greater inhibition of growth and induction of apoptosis in vitro than monotherapy treatment with these agents, indicating a synergistic interaction. Moreover, combination of AZD5363 and bicalutamide resulted in greater efficacy than AZD5363 monotherapy in LNCaP xenografts in vivo. The data show that whilst AZD5363 has considerable monotherapy activity in AR+/PTEN null prostate cancer models, the combination with anti-androgens merits further evaluation as a possible means to achieve greater anti-tumor activity. AZD5363 is currently in Phase 1 clinical trials. Citation Format: Claire Crafter, Barry R. Davies, Christian Thomas, Francois Lamoureux, Hannah Greenwood, Juan M. Garcia-Martinez, Lorraine Mooney, Sabina Cosulich, Martin Gleave, Amina Zoubeidi. Induction of apoptosis and antitumor activity of the AKT inhibitor AZD5363 is enhanced by combination with hormonal therapies in preclinical models of prostate cancer [abstract]. In: Proceedings of the AACR Special Conference on Advances in Prostate Cancer Research; 2012 Feb 6-9; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2012;72(4 Suppl):Abstract nr B19.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.010

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.103
GPT teacher head0.424
Teacher spread0.321 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2012
Admission routes1
Has abstractyes

Explore more

Same venueCancer Research→Same topicProstate Cancer Treatment and Research→French-language works237,207→